A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer (HER2CLIMB-04)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04539938 |
Recruitment Status :
Active, not recruiting
First Posted : September 7, 2020
Last Update Posted : March 6, 2024
|
Sponsor:
Seagen Inc.
Information provided by (Responsible Party):
Seagen Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Active, not recruiting |
---|---|
Estimated Primary Completion Date : | July 31, 2024 |
Estimated Study Completion Date : | October 31, 2025 |